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Background. The need for a highly efficacious vaccine against Plasmodium falciparum remains pressing. In this controlled
human malaria infection (CHMI) study, we assessed the safety, efficacy and immunogenicity of a schedule combining 2 distinct
vaccine types in a staggered immunization regimen: one inducing high-titer antibodies to circumsporozoite protein (RTS,S/
AS01B) and the other inducing potent T-cell responses to thrombospondin-related adhesion protein (TRAP) by using a viral vector.
Method. Thirty-seven healthy malaria-naive adults were vaccinated with either a chimpanzee adenovirus 63 and modified vac-
cinia virus Ankara–vectored vaccine expressing a multiepitope string fused to TRAP and 3 doses of RTS,S/AS01B (group 1; n = 20) or
3 doses of RTS,S/AS01B alone (group 2; n = 17). CHMI was delivered by mosquito bites to 33 vaccinated subjects at week 12 after the
first vaccination and to 6 unvaccinated controls.
Results. No suspected unexpected serious adverse reactions or severe adverse events related to vaccination were reported.
Protective vaccine efficacy was observed in 14 of 17 subjects (82.4%) in group 1 and 12 of 16 subjects (75%) in group 2. All control
subjects received a diagnosis of blood-stage malaria parasite infection. Both vaccination regimens were immunogenic. Fourteen
protected subjects underwent repeat CHMI 6 months after initial CHMI; 7 of 8 (87.5%) in group 1 and 5 of 6 (83.3%) in group
2 remained protected.
Conclusions. The high level of sterile efficacy observed in this trial is encouraging for further evaluation of combination
approaches using these vaccine types.
Clinical Trials Registration. NCT01883609.
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Malaria remains one of the leading causes of mortality globally
[1], and there is urgent need for a vaccine. The majority of
deaths are in children <5 years old, with this age group account-
ing for approximately 306 000 deaths in 2015. The enormous
economic and social consequences of malaria have been well
documented [2]. Efforts to develop effective vaccines are com-
plicated by the complex immunology of malaria parasite infec-
tion, and no reliable natural model of complete immunity exists.
Despite this, a small number of candidate vaccines have shown
partial efficacy against experimental and natural human infec-
tion, with the current leading vaccine being the recombinant
protein in adjuvant, RTS,S/AS01. RTS,S targets circumsporo-
zoite protein (CS), which is expressed by the Plasmodium falcip-
arum sporozoite at the preerythrocytic stage and was the first
subunit vaccine to show high rates of sterile efficacy, typically
50%, in controlled human malaria infection (CHMI) studies
[3]. In a large African phase 3 trial, this vaccine had an efficacy
against clinical malaria of 55.8% (97.5% confidence interval
[CI], 50.6%–60.4%) in children aged 5–17 months and 31.3%
(23.6%–38.3%) in infants aged 6–12 weeks over the first year
after vaccination [4, 5]. Vaccine efficacy wanes over time but
can be enhanced by a fourth dose [6]. Analysis of the immuno-
logical correlates of efficacy of this vaccine suggest that vaccine-
induced antibodies targeting CS are the most important medi-
ators of RTS,S-induced protection against malaria [3], although
no antibody level threshold has been shown to be predictive of
efficacy. The rate at which anti-CS antibodies wane is similar to
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the rate at which efficacy declines [7, 8], suggesting that anti-CS
antibodies may also be associated with the duration of protec-
tion. A number of factors, including age at vaccination, human
immunodeficiency virus status, and high baseline anti-CS anti-
body titers influence anti-CS antibody titers after vaccination
with RTS,S [9].
The preerythrocytic stage of P. falciparum infection presents
an attractive target for an efficacious human vaccine because
sufficient reduction in the number of viable merozoites reaching
the blood from the liver will prevent parasitization of red blood
cells and initiation of the symptomatic blood stage of infection.
Anti-CS antibodies can target sporozoites for destruction prior
to hepatocyte invasion. Because sporozoites travel from the skin
to liver within minutes, it may be difficult for a vaccine to
achieve complete protection against P. falciparum based solely
on antibodies to sporozoites. The liver stage of infection pro-
vides a longer window of opportunity for cell-mediated immu-
nity to recognize and destroy infected hepatocytes. Chimpanzee
adenovirus 63 (ChAd63) with a multiepitope string fused
to thrombospondin-related adhesion protein (ME-TRAP)
insert and modified vaccinia virus Ankara (MVA) with the
ME-TRAP insert are viral-vectored vaccines, and when they
are administered in a prime-boost sequence at an 8-week inter-
val, they are a leading candidate vaccine strategy targeting the
liver stage of infection [10]. The ChAd63 and MVAviral vectors
deliver the recombinant ME-TRAP insert, which generates
a potent cellular immune response against the liver-stage
P. falciparum antigen, TRAP, of greater magnitude than the cel-
lular response induced by RTS,S/AS01. This strategy showed
durable partial efficacy in 2 phase 2a sporozoite challenge trials
in the United Kingdom [11, 12], using the 3D7 parasite as a
challenge strain. The viral vector–encoded P. falciparum
TRAP allele is from the heterologous T9/96 strain, and induced
T-cell responses correlate with efficacy [11]. Therefore, these are
effectively heterologous strain CHMI studies. Interestingly, a
higher level of efficacy of 67% (95% CI, 33%–83%) against P.
falciparum infections detected by polymerase chain reaction
(PCR) was observed in a phase 2b trial in Kenyan adults [13].
Again, T cells to TRAP peptides correlated with vaccine efficacy,
but the short duration of malaria transmission and follow-up at
this trial site precluded analysis of the durability of vaccine-
induced protection [13].This heterologous prime-boost strategy
showed potent cellular immunogenicity in adults in the United
Kingdom [11], as well as adults and infants in malaria-endemic
areas [13–15] (Ewer et al, unpublished data) and has an excel-
lent track record of safety and tolerability in these populations.
Analysis of the potential utility of combining antisporozoite and
anti–liver-stage vaccines have suggested a likely additive or syn-
ergistic effect [16], in keeping with findings from preclinical
studies [17, 18].
In this phase 1/2a, open-labeled, CHMI study, we assessed
the safety, immunogenicity, and efficacy of a vaccine schedule
combining these 2 distinct candidate vaccine types in a stag-
gered immunization regimen: one that induces very high titer
antibodies to CS, using RTS,S/AS01B, and another that induces
potent T-cell responses to TRAP, using viral vectors.
METHODS
Participants
Recruitment and vaccination was conducted at 3 United King-
dom sites, in Oxford, Southampton and London. The CHMI
procedure was performed as previously described [19] at Impe-
rial College, London, using 5 infectious bites from Anopheles
stephensi mosquitoes infected with P. falciparum strain 3D7.
All subjects were infected with a single batch of mosquitoes at
the initial CHMI and with a second single batch at the repeat
CHMI. Infected mosquitoes were supplied by the Depart-
ment of Entomology, Walter Reed Army Institute of Research
(Washington D.C.). Healthy, malaria-naive males and nonpreg-
nant females aged 18–45 years were invited to participate in the
study. All volunteers gave written informed consent prior to
participation, and the study was conducted according to the
principles of the Declaration of Helsinki and in accordance
with good clinical practice (GCP).
Ethical and Regulatory Approval
Necessary approvals for the study were granted by the United
Kingdom National Research Ethics Service, Committee South
Central–Oxford A (reference 13/SC/0208), the Western Institu-
tion Review Board (reference 20130698), and the United King-
dom Medicines and Healthcare Products Regulatory Agency
(reference 21584/0317/001-0001). The trial was registered
with ClinicalTrials.gov (reference NCT01883609). The Local
Safety Committee provided safety oversight, and GCP compli-
ance was independently monitored externally by the Clinical
Trials and Research Governance Team of the University of
Oxford.
Study Design
This phase 2a, open-labeled, partially randomized challenge
trial consisted of 4 cohorts. Allocation to study group occurred
at screening and was based on subject preference. Any subjects
without a preference were randomly assigned to vaccine group 1
or vaccine group 2. Group 1 (n = 20) received 5 vaccinations
(RTS,S/AS01B 50 µg at 0, 4, and 8 weeks, ChAd63 ME-TRAP
5 × 1010 virus particles at 2 weeks, and MVA ME-TRAP
2 × 108 plaque-forming units at 10 weeks); group 2 (n = 20) re-
ceived 3 vaccinations (RTS,S/AS01B 50 µg at 0, 4, and 8 weeks);
and group 3 (n = 6) received no vaccinations. All vaccinations
were administered intramuscularly into the deltoid region of
the arm. In each volunteer, all RTS,S/AS01B injections were
given in one arm, and all viral vector injections were given in
the contralateral arm. All subjects underwent initial CHMI by
mosquito bite at the same time (week 12 after first vaccination
for vaccinated subjects). Following CHMI, a diagnosis of
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blood-stage malaria parasite infection was made in subjects with
symptoms suggestive of malaria and positive findings of thick
film microscopy or, if either thick film was negative or symp-
toms were absent, in subjects with a qPCR result of >500 para-
sites/mL [12]. Vaccinated subjects who had not developed
blood-stage malaria by day 21 after CHMI were deemed to ex-
hibit sterile protection and were invited to undergo repeat
CHMI 6 months later, for which an additional control group
(group 4) was recruited.
Further details of the study sites, inclusion/exclusion criteria,
vaccines, clinical follow-up, safety monitoring, malaria treat-
ment and diagnosis, immunological and molecular methods,
and statistical analysis can be found in the Supplementary
Materials.
RESULTS
Participants
Eighty subjects were screened for eligibility, and 48 subjects were
identified as eligible. Twenty subjects were allocated to group 1 to
receive RTS,S/AS01B and viral vectors encoding ME-TRAP. Sev-
enteen subjects were allocated to group 2 to receive RTS,S/AS01B
only. Six unvaccinated controls were recruited to group 3 for the
initial CHMI, and 5 subjects were allocated to group 4 for the re-
peat CHMI. Vaccinations took place between 2 September 2013
and 13 November 2013. Prior to CHMI, 3 subjects withdrew
from group 1, and 1 subject withdrew from group 2. There
were no withdrawals due to safety concerns, and no predefined
study stopping or holding rules were activated. CHMI was per-
formed on 25 and 26 November 2013, and repeat CHMI was per-
formed on 13 May 2014 (Figure 1).
Protective Efficacy Against CHMI
A total of 39 subjects participated in the initial CHMI (17 sub-
jects from group 1, 16 subjects from group 2, and 6 subjects
from group 3), which was conducted over 2 days. Three subjects
in group 1 and 4 subjects in group 2 received a diagnosis of
malaria before day 21 after challenge, resulting in a sterile effi-
cacy of 82.4% (95% CI, 64%–100%) and 75% (95% CI, 54–96),
Figure 1. Flow of study design and volunteer recruitment. Twenty-seven subjects were excluded because of inclusion/exclusion criteria. Three subjects withdrew consent
after screening but before enrollment. Two subjects were deemed eligible as control subjects but only after group 3 enrollment was complete. They were kept as backup
subjects in case of last-minute withdrawals from group 3 but never underwent controlled human malaria infection (CHMI). Seventeen subjects expressed a preference as to
which vaccine group to be allocated to and were assigned accordingly. Twenty subjects expressed no preference for vaccine group allocation, and were therefore randomized to
group by the study statistician. Abbreviations: ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple-epitope thrombospondin-related adhesion protein; MVA, mod-
ified vaccinia virus Ankara.
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respectively (Figure 2). The median time to diagnosis was 14.5
days in group 1 and 13.25 days in group 2. All 6 control subjects
received a diagnosis of malaria, with a median time to diagnosis
of 12.25 days (range, 11–13 days; SD, 0.7 days). Both vaccine
regimens demonstrated a significantly reduced risk of malaria
parasite infection over controls in the per protocol analysis
(group 1 hazard ratio [HR], 0.065; P < .0001; group 2 HR,
0.12; P < .0001 for group 2), but there was no significant differ-
ence in efficacy between vaccine regimen (HR, 0.65; P .57).
Eight protected subjects from group 1 and 6 protected subjects
from group 2 agreed to undergo repeat CHMI. A single subject
each from group 1 and group 2 received a diagnosis of malaria,
on day 17 and day 14.5, respectively, and all 5 control subjects
developed malaria, with a mean time to diagnosis of 12.4 days
(median, 12.5 days; range, 11.5–13.5 days; SD, 0.8 days).
Safety
The safety profile of a 3-dose regimen of RTS,S/AS01B and of
ChAd63-MVA ME-TRAP when given separately to malaria-
naive adults has been described previously [3, 10–12, 20], and
a similar reactogenicity profile was observed after vaccination
in this study. The majority of adverse events (AEs) following
vaccinations in both group 1 and group 2 were mild in severity
and self-limiting. There were no serious AEs related to vaccina-
tion, and no suspected, unexpected serious adverse reactions
(SUSARs). Solicited and unsolicited AEs following vaccination
are detailed in Supplementary Tables 1–12.
Humoral Response to Vaccination
Anti-TRAP IgG antibodies were measured in group 1 subjects
only (Figure 3), and geometric mean titers (GMTs) peaked
on the day before challenge, at 947 ELISA units (EU; 95% CI,
617–1455). No association was detected between anti-TRAP
IgG levels and efficacy (Spearman r = −0.25; P = .3). Anti-CS
antibodies were measured at key time points in all vaccinated
subjects. Serum anti-CS antibody levels peaked on the day be-
fore challenge in both vaccinated groups, with peak GMTs of
1733 EU (95% CI, 1240–2422) and 1824 EU (95% CI, 1330–
2502) in groups 1 and 2, respectively. There was no significant
difference in anti-CS antibody GMTs between group 1 and
group 2 on the day before challenge (P > .99, by the Mann–
Whitney test). Anti-CS antibody GMTs on the day before chal-
lenge were significantly higher in protected subjects (1985 EU
[95% CI, 1584–2487]), compared with those in nonprotected
subjects (1177 [95% CI, 627–2209]; P = .035, by the Mann–
Whitney test; Figure 3). There was a correlation between anti-
CS antibody titer and parasite density on day 7.5 (Spearman
r = −0.4; P = .018). There was no significant difference in the
avidity of anti-CS antibodies between protected and non-
protected volunteers at any time point, but avidity significantly
increased between day 28 and the day before challenge in pro-
tected but not nonprotected volunteers (P = .001 and P > .99, re-
spectively, by the Wilcoxon matched pairs test). Avidity also
Figure 2. Efficacy of RTS,S/AS01B plus chimpanzee adenovirus 63 and modified
vaccinia virus Ankara–vectored vaccine (ChAd63-MVA) expressing a multiepitope
string fused to thrombospondin-related adhesion protein (ME-TRAP) and RTS,S/
AS01B alone following Plasmodium falciparum 3D7 sporozoite challenge. A, Kaplan–
Meier survival analysis of the time to treatment following initial controlled human ma-
laria infection (CHMI). Mean time to diagnosis (± standard deviation [SD]) was 12.2±0.7
days for unvaccinated controls. Seventeen of 17 subjects (100%) in group 1 and 14 of 16
subjects (87.5%) in group 2 had no diagnosis by day 21 or received a diagnosis after the
control mean time + 2 SD. B, Kaplan–Meier survival analysis of the time to the first
sample with >20 parasites/mL detected by quantitative polymerase chain reaction
(qPCR). Mean time to end point (±SD) was 7.4±0.7 days for unvaccinated controls. Six-
teen of 17 subjects (94.1%) in group 1 and 15 of 16 subjects (93.8%) in group 2 did not
reach this end point or did so after the control mean time + 2 SD. C, Kaplan–Meier
survival analysis of the time to the first sample with >500 parasites/mL detected by
qPCR. Mean time to end point (±SD) was 9.8±0.8 days for unvaccinated controls. Sev-
enteen of 17 subjects (100%) in group 1 and 15 of 16 subjects (93.8%) in group 2 did
not reach this end point or did so after the control mean time + 2 SD. D, Kaplan–Meier
survival analysis of the time to treatment following repeat CHMI in protected subjects.
Significance testing was performed by the log-rank test.
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increased between day 56 and the day before challenge in pro-
tected but not nonprotected volunteers (P < .0001 and P = .375,
respectively, by the Wilcoxon matched pairs test). In the
protected vaccinated subjects who underwent repeat CHMI, avid-
ity on the day before rechallenge remained significantly higher
than at day 28 (P = .002, by the Mann–Whitney test).
Figure 3. Antibody responses to vaccination, measured by enzyme-linked immunosorbent assay (ELISA). A, Anti-thrombospondin adhesion protein (TRAP) immunoglobulin G
(IgG) antibody responses after vaccination with RTS,S/AS01B plus chimpanzee adenovirus 63 and modified vaccinia virus Ankara–vectored vaccine (ChAd63-MVA) expressing a
multiepitope string fused to TRAP (ME-TRAP; group 1 subjects only). Lines represent group medians. B, Anti–circumsporozoite protein (CS) IgG antibody responses after vac-
cination with RTS,S/AS01B plus ChAd63-MVA ME-TRAP (group 1; blue) or RTS,S alone (group 2; black). Line represents group median. C, Comparison of anti-CS IgG antibody
responses between group 1 (blue) and group 2 (black) as measured on the day before controlled human malaria infection (CHMI). P > .999, by the Mann–Whitney test. Com-
parison of anti-CS IgG antibody responses in volunteers who were or were not sterilely protected. Lines represent geometric means. D, Correlation between anti-CS IgG titers
on the day before challenge and parasite density on day 7 after challenge. Spearman r =−0.4; P = .018. E, Avidity of total IgG against the NANP repeat region of circum-
sporozoite protein. Significant increase in avidity between day 28 and the day before challenge in protected but not nonprotected volunteers. P = .001, by the Wilcoxon matched
pairs test. Avidity of total IgG remained significantly higher at time of the second CHMI (RC-1) than at day 28. P = .002, Mann–Whitney test. Lines represent geometric mean.
Abbreviations: C+, elapsed time after CHMI, in days; C-1, day before CHMI; PCR, polymerase chain reaction; RC-1, day before second CHMI.
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Cellular Response to Vaccination
T-cell responses against ME-TRAP were measured in all group
1 subjects by an ex vivo interferon γ (IFN-γ) enzyme-linked im-
munosorbent spot (ELISPOT) assay (Figure 4). Peak responses
after ChAd63 ME-TRAP vaccination were detected 21 days
later (Geometric Mean, 539 spot-forming cells [SFCs] per
million peripheral blood mononuclear cells [PBMCs]; 95%
CI, 300–968 SFCs per million PBMCs). Peak responses after
MVA ME-TRAP vaccination were detected 7 days later (medi-
an, 1520 SFCs per million PBMCs; interquartile range [IQR],
699–3305 SFCs per million PBMCs). T-cell responses against
ME-TRAP were well maintained over time, with a median of
464 SFCs per million PBMCs (IQR, 231–933 SFCs per million
PBMCs) 90 days after initial challenge and 342 SFCs per million
PBMCs (IQR, 143–815 SFCs per million PBMCs) in participat-
ing subjects the day before repeat CHMI.
T-cell responses against CS were measured in all vaccinated
subjects by an IFN-γ ELISPOT assay (Figure 4). Responses
peaked in group 1 on the day before challenge (4 weeks after
final dose of RTS,S/AS01B; median, 36 SFCs per million
PBMCs; IQR, 12–176 SFCs per million PBMCs), with a median
response of 12 SFCs per million PBMCs (IQR, 12–70 SFCs per
million PBMCs) in group 2 at the same time point. No associ-
ation between IFN-γ ELISPOT responses to TRAP or CS and
vaccine efficacy was detected (Spearman r = −0.01 [P = .98]
and r = −0.001 [P = .0996] for TRAP and CS, respectively).
Flow cytometry using intracellular cytokine staining (ICS)
was performed for CS and hepatitis B virus surface antigen
(HBsAg) on day 42 after the first vaccination and on the day
before challenge, using cryopreserved PBMCs. In this assay, re-
sponses were measured as the number of cells per million CD4+
or CD8+ T cells expressing at least 2 markers from among
CD154 (CD40 ligand), IFN-γ, interleukin 2, and tumor necrosis
factor α (Figure 5A and 5B). CS-specific CD4+ T-cell responses
peaked on day 42 (2 weeks after the second dose of RTS,S) in
both groups, and no significant differences were detected be-
tween groups 1 and 2 either on day 42 or the day before chal-
lenge (Figure 5C). CS-specific CD8+ T-cell responses were not
detected at any significant frequency. A positive association was
detected between the number of polyfunctional CD4+ T cells at
day 42 and the level of anti-CS IgG in serum on the day before
challenge (Spearman r = 0.4; P = .03; Figure 5D). Vaccination
with RTS,S increased the frequency of HBsAg-specific CD4+ pol-
yfunctional T cells in both groups at all time points after vacci-
nation (Figure 5E and 5F).
Flow cytometry was also performed on freshly isolated PBMCs,
using CS peptides (for groups 1 and 2) and ME-TRAP peptides
(for group 1 only) on the day before challenge. Group 1 responses
to TRAP T9/96 and 3D7 were comparable across all cytokines
and CD107a (P < .0001, by the Kruskal–Wallis test with the
Dunn correction), with all volunteers exhibiting at least 1 pos-
itive cytokine response to both TRAP strains (Figure 6A and
6B). A positive response to CS was observed in 15 of 17
group 1 volunteers (83%), compared with just 9 of 16 volunteers
in group 2 (56%), with a significantly higher frequency of IFN-
γ–producing CD4+ T cells in group 1 (Figure 6C).
Ex vivo IFN-γ ELISPOT analysis revealed a trend toward
higher responses to CS peptides in group 1 as compared to
group 2 (P = .0517, by the Mann–Whitney test on combined
groups); when assessed by peptide pool, a significant trend to-
ward higher responses was observed in pool 1 (P = .0380, by the
Mann–Whitney test). This is likely due to CS epitope(s) present
in the ME string of ChAd63 ME-TRAP and MVA ME-TRAP.
Ex vivo IFN-γ data suggest that this epitope lies toward the
N-terminus of CS, as identified by a significantly higher
group 1 response to peptide pool 1. The ME string contains 2
epitopes present in pool 1: CD8 epitope cp26 KPKDELDY and
CD4 epitope DPNANPN, as part of a longer ME sequence,
DPNANPNNVDPNANPNV (Table 1). As the main differences
in ICS-determined IFN-γ production were in the CD4+ T-cell
Figure 4. Antigen-specific T-cell responses to vaccination, measured by interferon γ (IFN-γ) enzyme-linked immunospot assay (ELISPOT). A, Median T-cell responses to
multiepitope string fused to thrombospondin-related adhesion protein (ME-TRAP). B, Median T-cell responses to circumsporozoite protein (CS) peptide pools are shown for
group 1 (RTS,S/AS01 and ME-TRAP; blue line) and group 2 (RTS,S/AS01; black line). Abbreviations: ChAd63, chimpanzee adenovirus 63; MVA, modified vaccinia virus Ankara;
PBMC, peripheral blood mononuclear cell; SFC, spot-forming cell.
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compartment, epitope DPNANPN could be responsible for the
enhanced CS responses in group 1. This epitope is not present
in RTS,S, so it was solely induced by ChAd63.MVA ME-TRAP
prime boost vaccination.
DISCUSSION
Both RTS,S/AS01B and ChAd63-MVA encoding ME-TRAP
have previously demonstrated partial efficacy in CHMI trials
[3, 11, 12, 20], but this is the first study in which RTS,S/AS01B
and ChAd63-MVA ME-TRAP have been given to subjects in
the same vaccine regimen. In this study, we have shown that ad-
ministering these vaccines sequentially is safe, with no SUSARs
and no vaccine-related serious AEs. The reactogenicity profile
observed in the subjects who received the combined vaccine
regimen (group 1) was similar to that observed when RTS,
S/AS01B or ChAd63-MVAME-TRAP were given alone in a ma-
laria-naive adult population [3, 11, 12, 20].
Furthermore, we have demonstrated that these vaccine candi-
dates remain immunogenic when the regimens are combined.
Anti-CS antibodies were not significantly different between
Figure 5. T-cell responses determined by flow cytometry on cryopreserved peripheral blood mononuclear cells before and after vaccination for circumsporozoite protein (CS)
and hepatitis B virus surface antigen (HBsAg). Polypositivity indicates number of cells per million expressing ≥2 of the following markers: CD154 (CD40 ligand), interferon γ
(IFN-γ), interleukin 2 (IL-2), and tumor necrosis factor α (TNF-α). A and B, Number of CS-specific polypositive CD4+ or CD8+ T cells per million in groups 1 and 2, respectively.
C, Comparison of CD4+ polypositive T cells at peak time point after vaccination (day 42) and the day before controlled human malaria infection (CHMI) for groups 1 (G1) and 2
(G2). D, Correlation between peak CS-specific CD4+ polypositive frequency and anti-CS IgG level on the day before challenge (r = 0.4; P = .03, by the Spearman test). E and F,
Number of HBsAg-specific polypositive CD4+ or CD8+ T cells per million in groups 1 and 2, respectively. Abbreviations: C+, elapsed time after CHMI, in days; C-1, day before
CHMI; IgG, immunoglobulin G.
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group 1 and group 2 on the day before challenge, and peak
numbers of TRAP-specific T cells in group 1 were similar to
those observed with ChAd63-MVA ME-TRAP administered
alone in a previous study [11]. GMTs of anti-CS antibodies
were significantly higher in protected subjects on the day before
challenge, but there was no correlation between any TRAP- or
CS-specific T cell counts or TRAP-specific IgG and protection.
In this study, we observed a high level of protective efficacy in
both vaccine arms. A higher proportion of subjects in group 1
remained protected following CHMI than in group 2 (82.4% vs
75%), although this difference was not statistically significant
(P = .57). This high level of vaccine efficacy was also seen to
be durable at 6 months, with 87.5% and 83.3% of initially pro-
tected subjects who underwent repeat CHMI remaining pro-
tected in groups 1 and 2, respectively. In addition, a higher
proportion of subjects in group 1 reached the secondary efficacy
end points of delayed time to malaria diagnosis and delayed
time to PCR-confirmed parasitemia, compared with group
Figure 6. Intracellular cytokine staining of peripheral blood mononuclear cells (PBMCs) 1 day before controlled human malaria infection (CHMI; 27 days after the final RTS,S
vaccination and 13 days after vaccination with modified vaccinia virus Ankara [MVA] expressing a multiepitope string fused to thrombospondin-related adhesion protein [ME-
TRAP]), showing the CD107a expression frequency and the frequencies of cytokine-secreting cells as a percentage of the frequency of parent CD4+ and CD8+ T cells. Geometric
mean of each response is shown in response to stimulation with TRAP T9/96 peptides (homologous to vaccine insert) by group 1 (A), TRAP 3D7 peptides (homologous to CHMI
challenge strain) by group 1 (B), and circumsporozoite (CS) peptides by groups 1 and 2 (C). D, Ex vivo interferon γ enzyme-linked immunospot (ELISPOT)–determined responses of
group 1 and 2 volunteers to CS peptides split into 3 peptide pools and a combined pool, with background subtracted. Dotted line shows the median background ELISPOT
response, setting the positive response threshold. Data are for 17 individuals in group 1 and 16 in group 2. Data points represent individual volunteers. Abbreviations: IFN-γ,
interferon γ; IL-2, interleukin 2; SFC, spot-forming cell; TNF-α, tumor necrosis factor α.
Table 1. Comparison of Peptide Sequences Present in the Multiepitope (ME) String Fused to Thrombospondin-Related Adhesion Protein and the T-Cell
Region of RTS,S
Epitope Sequence
CS Amino Acid
Position (Length)
Epitope
Type
Present in
ME String
Present in
RTS,S
Present in ELISPOT
CS Peptides
ELISPOT Pool
Number
DPNANPNVDP NANPNV 111–126 (16) CD4 Yes No Yes, DNANPN only 1
NMPNDPN RNV 286–293 (8) CD8 Yes Yes Yes, PNDPN RNV only 1
YL NKIQNSL 319–327 (9) CD8 Yes Yes Yes, full length 2
KPKDELDY 353–360 (8) CD8 Yes Yes Yes, full length 3
Data are from Lalvani et al [21].
Abbreviations: CS, circumsporozoite protein; ELISPOT, enzyme-linked immunospot.
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2. The trends observed in this study for initial challenge, rechal-
lenge, and effects on the prepatent period are encouraging for
further evaluation of the group 1 regimen, but the numbers in
this study are small, and the differences observed not statisti-
cally significant. In 2013, a CHMI study of the cryopreserved
whole sporozoite (PfSPZ) vaccine reported sterile efficacy
of 100% in the high-dose regimen, consisting of 5 doses of
1.35 × 105 parasites [22]. However, the vaccinee numbers in
the high-dose group were small (n = 6), and only 5 of 6 unvac-
cinated controls (83.3%) developed blood-stage infection, rais-
ing concerns over the infectivity of the parasites used in that
CHMI. The results observed in the trial we present in this article
therefore are amongst the highest published sterile vaccine effi-
cacy in any CHMI study in which all control subjects were
infected.
The level of protective efficacy observed in the RTS,S/AS01B
alone group (75%) is higher than has been reported in most
prior CHMI studies of this vaccine regimen [3, 20]. The mean
time to patency in the control group of 12.2 days indicates that
this was not an unusually weak challenge, and the vaccination
and CHMI methods used in this trial are largely comparable to
those in other CHMI studies of this dosing schedule of RTS,S/
AS01 [3]. Practical limitations on study size are a factor for both
this study and prior CHMI studies of RTS,S, resulting in a rel-
atively small historical data set. In light of this, it is possible that
the higher efficacy seen in the RTS,S alone group in this trial is a
chance finding due in part to small numbers, or that further
CHMI studies of RTS,S/AS01 in malaria-naive subjects, includ-
ing further evaluation of differing dosing regimens and sched-
ules, would further clarify the efficacy of the vaccine in this
setting. The study was designed to have 84% power to detect
a significant (P < .05) increase in sterile efficacy in group 1 to
90% and 69% power to detect a significant increase to 85%,
compared with group 2. This power calculation assumed an ex-
pected 50% sterile efficacy in group 2 [3]. The increase in effi-
cacy to 82.4% in group 1 from 75% in group 2 observed in this
trial was not statistically significant (P = .69), but the power to
detect a statistically significant improvement was very limited.
Practical limitations of CHMI trials makes conducting large
studies difficult, and designing future studies with sufficient
power would be complicated, assuming an efficacy of 75% in
an RTS,S/AS01B alone group. One alternative approach is to
wait longer after immunization, to allow vaccine efficacy to
wane and thereby provide greater power to detect additive or
synergist effects of combination vaccines. Further consideration
of this issue and of the practical limitations of CHMI studies
with challenge 3–4 weeks after the last vaccination in future
trial designs is warranted.
We undertook a rechallenge of protected subjects 6 months
after the initial CHMI, and 7 of 8 group 1 subjects (87.5%) and 5
of 6 group 2 subjects (83.3%) remained protected. By simply
calculating the product of the percentage efficacies in the 2
CHMIs, one can estimate vaccine efficacy at 6–7 months after
the immunizations as a measure of durable sterile protection.
For group 1, this is 72% [(14/17) ×( 7/8) × 100], and for group
2, it is 62.5% [(12/16) × (5/6) × 100)]. Again, the durable protec-
tion rate at this time point in group 2 appears higher than in
previous rechallenge trials with RTS,S/AS01B administered 3
times [3], and the group 1 protection rate is even higher. This
durability at 6 months is also encouraging for continued inves-
tigation of combination vaccine approaches and supports the
consideration of delayed CHMI as an approach to evaluating
improvements in efficacy provided by vaccines that confer sub-
stantial short-term efficacy.
In this trial, we present data from a combined vaccine regi-
men in which subjects received 5 vaccinations over a 10-week
period. A priority for future studies should be to evaluate the
effect of simplifying the vaccination schedule. A study evaluat-
ing the concomitant administration of RTS,S with viral vectors
expressing ME-TRAP, thereby reducing the total number of
vaccinations in a more practical schedule for potential deploy-
ment, is currently underway. These results are encouraging for
further evaluation of malaria vaccine regimens that combine
viral vectors with protein subunits and also vaccine regimens
that target multiple stages of the malaria parasite life cycle.
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